🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "major milestone" in the battle against superbug strains of the infection, according to scientists.

A Global Public Health Issue

Gonorrhoea infections are increasing globally, with figures suggesting in excess of 82 million instances per year. Especially elevated rates are seen in the African continent and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune development in the context of increasing worldwide cases, escalating drug resistance and the highly restricted treatment choices currently available.”

Medical experts are particularly alarmed about the rise in drug-resistant strains. The WHO has designated it as a "high-priority threat". Recent surveillance revealed that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Receive Clearance

One new antibiotic, marketed under the name Nuzolvence, was authorized by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to serious health problems, including infertility. Experts anticipate that targeted use of this new drug will help delay the development of resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, also received approval in close succession. This medication, which is employed against urinary tract infections, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This milestone marks a huge turning point in the treatment of highly resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Research Study Results and Worldwide Availability

Based on results detailed in a prominent scientific publication, the new drug cured more than 90% of cases of the STI. This establishes an equal footing with the current standard treatment, which combines a dual-drug approach. The study included hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the authority to register and commercialise the drug in many regions with limited resources.

Clinicians on the front lines have shared optimism. The availability of a one-pill regimen such as this is hailed as a "critical tool" for gonorrhoea control. This is deemed crucial to reduce the burden of the infection for patients and to prevent the spread of untreatable gonorrhoea globally.